Johnson & Johnson (NYSE:JNJ) Shares Purchased by Ballast Advisors LLC

Ballast Advisors LLC boosted its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 1.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,377 shares of the company’s stock after acquiring an additional 151 shares during the period. Johnson & Johnson accounts for 0.6% of Ballast Advisors LLC’s portfolio, making the stock its 27th largest position. Ballast Advisors LLC’s holdings in Johnson & Johnson were worth $1,604,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. increased its stake in Johnson & Johnson by 1.9% during the third quarter. BlackRock Inc. now owns 195,038,467 shares of the company’s stock valued at $31,498,715,000 after purchasing an additional 3,653,357 shares during the last quarter. Geode Capital Management LLC increased its stake in Johnson & Johnson by 2.6% during the third quarter. Geode Capital Management LLC now owns 43,320,776 shares of the company’s stock valued at $6,977,300,000 after purchasing an additional 1,106,544 shares during the last quarter. Morgan Stanley increased its stake in Johnson & Johnson by 3.1% during the second quarter. Morgan Stanley now owns 25,066,744 shares of the company’s stock valued at $4,129,496,000 after purchasing an additional 760,796 shares during the last quarter. Nordea Investment Management AB increased its stake in Johnson & Johnson by 102.3% during the third quarter. Nordea Investment Management AB now owns 19,399,590 shares of the company’s stock valued at $3,189,681,000 after purchasing an additional 9,808,798 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in Johnson & Johnson by 1.7% during the third quarter. Franklin Resources Inc. now owns 16,392,226 shares of the company’s stock valued at $2,647,348,000 after purchasing an additional 273,957 shares during the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

In other news, VP Thibaut Mongon sold 23,681 shares of the company’s stock in a transaction dated Thursday, March 17th. The stock was sold at an average price of $176.25, for a total value of $4,173,776.25. The sale was disclosed in a filing with the SEC, which is accessible through this link. 0.35% of the stock is owned by corporate insiders.

Several research firms have recently commented on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a research report on Thursday, March 31st. They set a “strong-buy” rating for the company. Sanford C. Bernstein lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and upped their price target for the stock from $180.00 to $183.00 in a research report on Wednesday, March 16th. Bank of America began coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating for the company. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Finally, Raymond James increased their target price on shares of Johnson & Johnson from $185.00 to $195.00 and gave the company an “outperform” rating in a research report on Thursday. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Buy” and a consensus target price of $184.57.

JNJ stock traded down $1.97 during mid-day trading on Monday, reaching $177.93. 189,244 shares of the stock traded hands, compared to its average volume of 7,804,213. The company has a current ratio of 1.35, a quick ratio of 1.12 and a debt-to-equity ratio of 0.41. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $184.20. The company has a market cap of $467.83 billion, a P/E ratio of 23.03, a P/E/G ratio of 2.71 and a beta of 0.72. The stock’s fifty day moving average is $172.37 and its 200-day moving average is $167.89.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings data on Tuesday, January 25th. The company reported $2.13 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.01. Johnson & Johnson had a net margin of 22.26% and a return on equity of 37.46%. The company had revenue of $24.80 billion during the quarter, compared to analyst estimates of $25.29 billion. During the same period in the prior year, the firm earned $1.86 earnings per share. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Equities research analysts expect that Johnson & Johnson will post 10.48 earnings per share for the current year.

About Johnson & Johnson (Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.